John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 21,904 shares at $7.57 ($165K) on 2022-02-25, disclosed to the SEC on 2022-02-28.
Open-market sale of $165k FUSN by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.41 | 2,500 | $19K | 11.2% |
| 2 | $7.57 | 8,152 | $62K | 37.4% |
| 3 | $7.57 | 8,152 | $62K | 37.4% |
| 4 | $7.40 | 3,100 | $23K | 13.9% |
| Total | $7.53 avg | 21,904 | $165K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |